We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Effect of MED-02 Containing Two Probiotic Strains, Limosilactobacillus fermentum MG4231 and MG4244, on Body Fat Reduction in Overweight or Obese Subjects: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study.
- Authors
Cho, Young Gyu; Yang, Yun Jun; Yoon, Yeong Sook; Lee, Eon Sook; Lee, Jun Hyung; Jeong, Yulah; Kang, Chang Ho
- Abstract
MED-02 is a complex supplement containing two probiotic strains, Limosilactobacillus fermentum MG4231 and MG4244, isolated from humans. The anti-obesity effects and safety profile of MED-02 were assessed in overweight and obese subjects. In this randomized, double-blinded, placebo-controlled, multicenter study, 100 healthy obese and overweight subjects aged 19–65 years with a body mass index (BMI) between 25 and 31.9 kg/m2 were recruited and randomized to receive a placebo or MED-02 (5 × 109 CFU/day). After 12 weeks of consumption, body fat mass (−1166.82 g vs. −382.08 g; p = 0.024) and body fat percentage (−0.85% vs. −0.11%; p = 0.030), as evaluated by dual-energy X-ray absorptiometry (DEXA) and body weight (−2.06 kg vs. −1.22 kg; p = 0.041), were significantly reduced in the MED-02 group compared to the placebo group. The safety profile did not differ among the groups. No serious adverse effects were observed in either group. These results suggest that MED-02 is a safe and beneficial probiotics that reduces body fat and body weight in overweight or obese individuals.
- Subjects
THERAPEUTIC use of probiotics; OBESITY; BODY composition; RESEARCH; PHOTON absorptiometry; BODY weight; PROBIOTICS; PLACEBOS; TREATMENT effectiveness; RANDOMIZED controlled trials; BLIND experiment; LACTOBACILLUS; STATISTICAL sampling; BODY mass index; FERMENTATION
- Publication
Nutrients, 2022, Vol 14, Issue 17, p3583
- ISSN
2072-6643
- Publication type
Article
- DOI
10.3390/nu14173583